Bispecific T-Cell Engagers Show Potential for Resetting the Immune System in Refractory Autoimmune Disease

Bispecific T-cell engagers (BiTEs) are emerging as a promising strategy to achieve an “immune reset” in patients with severe, refractory autoimmune diseases by eradicating pathogenic B cells and plasma cells within deep tissue niches. According to clinical data presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) meeting, these engineered molecules force a direct interaction between T cells and disease-driving immune cells, potentially overcoming the limitations of conventional monoclonal antibodies like rituximab.

Why Conventional B-Cell Therapies Often Fail

Standard treatments in rheumatology, such as rituximab, rely on anti-CD20 monoclonal antibodies to deplete B cells. However, these therapies often fail to produce a sustained clinical response because they cannot reach cells sequestered in deep tissue environments like the bone marrow or lymph nodes, according to Wolfgang Merkt, MD, of Heidelberg University. Because these treatments depend on the patient’s own innate immune system to clear the targeted cells, they frequently leave behind long-lived, CD20-negative plasma cells. These residual cells continue to function as autonomous “factories” for autoantibodies, driving persistent disease activity despite intensive treatment.

How Bispecific T-Cell Engagers Work

BiTEs bypass the limitations of traditional antibody-dependent cellular cytotoxicity by acting as a physical bridge between immune cells. Each molecule features two distinct binding arms: one locks onto a specific marker on a pathogenic B cell or plasma cell—such as CD19, CD20, or B-cell maturation antigen (BCMA)—while the other arm grabs a T cell. By pulling these cells into close proximity, the BiTE forces the T cell to form a synthetic cytotoxic synapse. The T cell then releases perforins and granzymes to destroy the target cell directly. This mechanism is independent of the host’s baseline immune function, allowing for more precise depletion within protected tissue niches.

Comparing Teclistamab, Blinatumomab, and Mosunetuzumab

Different BiTE modalities offer varying clinical profiles depending on their molecular structure and target antigen:

• Teclistamab: An IgG-based molecule targeting BCMA and CD3. Its full fragment crystallizable (Fc) domain provides a longer half-life, allowing for subcutaneous administration. It is specifically designed to eliminate mature plasma cells and plasmablasts.
• Blinatumomab: A small fragment-based molecule targeting CD19 and CD3. Because it lacks an Fc region, it has a short half-life of roughly two hours and requires continuous 24-hour intravenous infusion. It is highly effective at clearing peripheral B cells but carries a risk of rapid repopulation from bone marrow precursors.
• Mosunetuzumab: A full-length IgG molecule targeting CD20 and CD3. It focuses on mature B cells while sparing the plasma cell niche, which may reduce the risk of profound hypogammaglobulinemia compared to BCMA-targeted therapies.

Safety and Clinical Considerations

While BiTEs offer potency, they require careful clinical management. In a cohort of 18 patients with multidrug-refractory autoimmune diseases, researchers observed cytokine release syndrome (CRS) in 83% of cases, according to data presented by Ricardo Grieshaber-Bouyer, MD, of Friedrich-Alexander University Erlangen-Nürnberg. These events were classified as low-grade (grade 1 or 2) and were managed using the interleukin-6 receptor antagonist tocilizumab. Because BCMA-targeting therapies eliminate long-lived plasma cells, patients typically experience hypogammaglobulinemia, necessitating proactive substitution with intravenous immunoglobulin (IVIG).

The Future of Sequential Therapy

Experts are now evaluating whether these therapies can be used sequentially to rescue patients who fail to respond to other advanced interventions. Clinical data presented at EULAR 2026 showed that patients with systemic sclerosis who relapsed after CD19 CAR T-cell therapy were successfully treated with teclistamab. However, physicians caution that these therapies are primarily induction tools meant to quench active inflammation. According to Dr. Merkt, they cannot reverse structural damage or established scarring in organs. Future treatment protocols will likely pair cellular depletion with anti-fibrotic or stroma-directed treatments to address both the autoimmune driver and the resulting tissue destruction.

Key Takeaways

• BiTEs enable “deep tissue” depletion of immune cells, a feat that traditional anti-CD20 therapies often fail to achieve.
• BCMA-targeted BiTEs, such as teclistamab, are being repurposed from oncology to address refractory autoimmune conditions like Graves disease and IgG4-related disease.
• Safety monitoring is essential, particularly regarding CRS and the inevitable depletion of protective antibodies, which requires IVIG replacement.
• BiTEs are not a cure for chronic structural fibrosis; they are most effective as early-stage induction therapy to stop active disease progression.